Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Earendil Labs ADC Licensing Deal

Simply Wall St.03-01

WuXi XDC Cayman (SEHK:2268) just expanded its ADC platform reach as Earendil Labs secured an exclusive global license to the WuXiTecan-2 payload-linker technology, structured with upfront, milestone ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616530828?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-03-01 09:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616530828","market":"nz","top_or_hot":-1,"title":"Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Earendil Labs ADC Licensing Deal","media":"Simply Wall St.","content":"<div>\n<p>WuXi XDC Cayman (SEHK:2268) just expanded its ADC platform reach as Earendil Labs secured an exclusive global license to the WuXiTecan-2 payload-linker technology, structured with upfront, milestone ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-earen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Earendil Labs ADC Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing WuXi XDC Cayman (SEHK:2268) Valuation After New Earendil Labs ADC Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-01 09:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-earen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WuXi XDC Cayman (SEHK:2268) just expanded its ADC platform reach as Earendil Labs secured an exclusive global license to the WuXiTecan-2 payload-linker technology, structured with upfront, milestone ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-earen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-earen","article_id":"2616530828","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-earen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616530828","pubTimestamp":1772328295,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"WuXi XDC Cayman (SEHK:2268) just expanded its ADC platform reach as Earendil Labs secured an exclusive global license to the WuXiTecan-2 payload-linker technology, structured with upfront, milestone and royalty economics.\nSee our latest analysis for WuXi XDC Cayman.\nThe Earendil Labs agreement, which highlights WuXi XDC Cayman’s ADC and payload platform, comes as the shares trade at HK$63.15, with a 1 day share price return of 8.23%, a 30 day share price return of 2.02%, and a 1 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK1141":"生命科学工具和服务","02268":"药明合联","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","ADC":"艾格里房产"},"translate_title":"评估新Earendil Labs ADC许可协议后WuXi XDC Cayman(SEHK：2268)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1.5,"02268":0.9,"DCF":1},"content_text":"WuXi XDC Cayman (SEHK:2268) just expanded its ADC platform reach as Earendil Labs secured an exclusive global license to the WuXiTecan-2 payload-linker technology, structured with upfront, milestone and royalty economics. See our latest analysis for WuXi XDC Cayman. The Earendil Labs agreement, which highlights WuXi XDC Cayman’s ADC and payload platform, comes as the shares trade at HK$63.15, with a 1 day share price return of 8.23%, a 30 day share price return of 2.02%, and a 1 year total shareholder return of 96.42%. This suggests that long term momentum has been strong even if shorter term share price moves have been more muted recently. If this ADC licensing news has your attention, it could be a good moment to see what else is emerging in the sector by checking out our screener of 113 healthcare AI stocks. With WuXi XDC Cayman trading at HK$63.15 and sitting at a reported intrinsic discount of 55% plus a 34% gap to analyst targets, you have to ask: is this a genuine opportunity, or is the market already baking in future growth? AdvertisementPrice-to-Earnings of 52.5x: Is it justified? On a P/E of 52.5x at HK$63.15, WuXi XDC Cayman is priced above both its peer group and the level suggested by our fair-value P/E work. The P/E multiple compares the share price with earnings per share, so a higher figure usually reflects strong growth expectations or a quality premium. For a contract research, development, and manufacturing business focused on antibody drug conjugates and bioconjugates, investors often look at this multiple to gauge how much future profit is already reflected in the price. Here, the current P/E of 52.5x sits above the Asian Life Sciences industry average of 43.6x and also above the peer group average of 46.2x. This implies the market is paying a clear premium versus others in the space. Compared with an estimated fair P/E of 29.6x, the market multiple is also well ahead of the level our fair ratio work suggests it could converge toward. Explore the SWS fair ratio for WuXi XDC Cayman Result: Price-to-Earnings of 52.5x (OVERVALUED) However, you still need to weigh risks such as any slowdown in ADC demand or contract wins, as well as potential compression of that 52.5x P/E premium. Find out about the key risks to this WuXi XDC Cayman narrative. Another View: What Does The DCF Say? While the 52.5x P/E makes WuXi XDC Cayman look expensive, our DCF model points in the opposite direction. At HK$63.15, the shares are trading at a reported 55.1% discount to an estimated future cash flow value of HK$140.73. This frames the current price as potentially cheap rather than stretched. Which signal do you put more weight on? Look into how the SWS DCF model arrives at its fair value. 2268 Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out WuXi XDC Cayman for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 219 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of signals feels balanced between promise and concern, act while the data is fresh, check the details for yourself, and weigh 3 key rewards and 1 important warning sign before you decide where you stand. Looking for more investment ideas? If this story has sharpened your thinking, do not stop here. Use the same tools to scan other opportunities and keep your watchlist working for you.  Target potential mispricing by reviewing our list of 219 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them. Strengthen your income stream by checking out 449 dividend fortresses, focusing on companies offering higher yields with an emphasis on resilience. Protect your downside by scanning 324 resilient stocks with low risk scores that score well on financial health and business risk factors.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if WuXi XDC Cayman might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616530828","isCrawlerRequest":true}